What do systematic reviews say?

Fluoxetine vs placebo

• Fluoxetine for adults who are overweight or obese 2019 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 956 participants
  Very low

Fluoxetine vs placebo

The review found no eligible studies for this question.

• Fluoxetine for adults who are overweight or obese 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Fluoxetine vs placebo

Summary of findings: fluoxetine showed no clear difference in any adverse event (N) compared with placebo (low certainty).

• Fluoxetine for adults who are overweight or obese 2019 · Cochrane Headline outcomes only
  RR 1.18 [0.99, 1.42]
  9 studies · 1253 participants
  Low

Fluoxetine vs placebo

• Fluoxetine for adults who are overweight or obese 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 97 participants
  Very low

Fluoxetine vs placebo

It is very uncertain whether summary of findings: fluoxetine changes morbidity: depression (N) compared with placebo (very low certainty).

• Fluoxetine for adults who are overweight or obese 2019 · Cochrane Headline outcomes only
  RR 1.2 [0.57, 2.52]
  3 studies · 393 participants
  Very low

Fluoxetine vs placebo

The review found no eligible studies for this question.

• Fluoxetine for adults who are overweight or obese 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Fluoxetine vs placebo

The review found no eligible studies for this question.

• Fluoxetine for adults who are overweight or obese 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: insulin detemir vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  4.97 [0.79, 31.38]
  9 studies · 3334 participants
  Moderate

Summary of findings: insulin detemir vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 763 participants
  Low

Summary of findings: insulin detemir vs insulin glargine

The review found no eligible studies for this question.

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: insulin detemir vs insulin glargine

It is very uncertain whether summary of findings: insulin detemir changes severe hypoglycaemia (n/N) Definition: hypoglycaemia requiring third… compared with insulin glargine (very low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.59 [0.13, 2.63]
  2 studies · 763 participants
  Very low

Summary of findings: insulin detemir vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 443 participants
  Low

Summary of findings: insulin detemir vs insulin glargine

It is very uncertain whether summary of findings: insulin detemir changes severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with insulin glargine (very low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.55 [0.06, 5.12]
  2 studies · 763 participants
  Very low

Summary of findings: insulin detemir vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 870 participants
  Low

Summary of findings: insulin detemir vs insulin glargine

Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 1.72 [0.91, 3.28]
  2 studies · 763 participants
  Low

Summary of findings: insulin detemir vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 763 participants
  Low

Summary of findings: insulin detemir vs NPH insulin

Summary of findings: insulin detemir probably leads to lower severe hypoglycaemia (n/N) Definition: hypoglycaemia requiring third… compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.69 [0.52, 0.92]
  8 studies · 3219 participants
  Moderate

Summary of findings: insulin detemir vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 495 participants
  Low

Summary of findings: insulin detemir vs NPH insulin

Summary of findings: insulin detemir showed no clear difference in severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.67 [0.39, 1.17]
  7 studies · 2925 participants
  Moderate

Summary of findings: insulin detemir vs NPH insulin

Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.95 [0.75, 1.21]
  9 studies · 3332 participants
  Moderate